9987 Carver Road
Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.
Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-a (HIF1-a) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-a stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.
The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.